A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

Inclusion Criteria: * Life expectancy of at least 12 weeks * Measurable disease, as defined by the protocol * Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody * Best response of stable disease or better with at least one prior anti-CD38 monoclonal antibody containing line of treatment Exclusion Criteria: * Any anti-cancer therapy within 3 weeks prior to initiation of study treatment, with exceptions defined by the protocol * Prior allogeneic stem cell or solid organ transplantation * Autologous stem cell transplantation within 100 days prior to initiation of study treatment * Significant cardiovascular disease * Known clinically significant liver disease * Active or history of autoimmune disease or immune deficiency * Known active infection requiring IV anti-microbial therapy within 14 days prior to first study drug administration * Primary or secondary plasma cell leukemia * Current CNS involvement by MM * Other protocol defined inclusion/exclusion criteria may apply